Cogent Biosciences (COGT) director Arlene Morris receives grant of 17,901 stock options

Rhea-AI Filing Summary

Cogent Biosciences director Arlene Morris received a stock option grant for 17,901 shares of common stock. The options have an exercise price of $31.98 per share and expire on June 9, 2036, representing compensation rather than an open-market trade.

The option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the 2027 Annual Meeting of Stockholders, provided she continues serving the company through that date. After this grant, she directly holds stock options covering 17,901 underlying shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Morris Arlene

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,901	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 17,901 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 17,901 options Exercise price: $31.98 per share Underlying shares: 17,901 shares +2 more

5 metrics

Options granted 17,901 options Stock option grant on June 9, 2026

Exercise price $31.98 per share Stock option exercise price

Underlying shares 17,901 shares Common stock underlying the options

Expiration date June 9, 2036 Option expiration

Post-grant option holdings 17,901 options Total options directly held after grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, Annual Meeting of Stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 31.9800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-09T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Annual Meeting of Stockholders financial

"earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders"

vest in full financial

"This stock option shall vest in full upon the earlier of the first anniversary"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morris Arlene

(Last) (First) (Middle)

C/O COGENT BIOSCIENCES, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cogent Biosciences, Inc. [ COGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$31.98	06/09/2026		A		17,901		(1)	06/09/2036	Common Stock	17,901	$0	17,901	D

Explanation of Responses:

1. This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

	/s/ Evan D. Kearns, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Cogent Biosciences (COGT) director Arlene Morris report on this Form 4?

Arlene Morris reported receiving a grant of stock options for 17,901 shares of Cogent Biosciences common stock. The award is compensation-based, not an open-market purchase or sale, and reflects additional equity incentives tied to her continued board service.

How many Cogent Biosciences (COGT) shares are covered by the new stock options?

The new stock option grant covers 17,901 underlying shares of Cogent Biosciences common stock. These options represent potential future share ownership if exercised, subject to vesting conditions and the specified exercise price of $31.98 per share.

What is the exercise price and expiration date of Arlene Morris’s Cogent Biosciences options?

The stock options have an exercise price of $31.98 per share and expire on June 9, 2036. This gives the director a long-dated right to buy shares at that price once the options are fully vested.

When do the Cogent Biosciences (COGT) options granted to Arlene Morris vest?

The stock options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Vesting is contingent on Arlene Morris continuing to serve Cogent Biosciences through that vesting date.

Is Arlene Morris buying or selling Cogent Biosciences (COGT) stock in this filing?

This filing reflects a grant of stock options, not a market transaction. Arlene Morris is acquiring options as compensation rather than buying or selling shares on the open market, so there is no immediate trading in Cogent Biosciences stock.